Summary
Guardant Health, Inc. (GH) announced on January 7, 2019, that its LUNAR assay, designed for early-stage cancer detection and recurrence monitoring, is now available for research use. This development is significant as it leverages insights from over 80,000 patients tested with their existing Guardant360 liquid biopsy test, as well as whole-genome sequencing data. The availability for research purposes will allow biopharmaceutical and academic institutions to explore its utility in critical areas such as adjuvant therapy decision-making, recurrence monitoring, and cancer screening.
Key Highlights
- 1Guardant Health's LUNAR assay, a new blood-based test for early cancer detection and recurrence, is now available for research use.
- 2The LUNAR assay is built upon extensive biological insights from over 80,000 Guardant360 test patients and whole-genome sequencing data.
- 3The assay will be utilized by leading academic and biopharmaceutical research groups in studies related to cancer treatment decisions and monitoring.
- 4A clinical version of the LUNAR assay is anticipated to launch in the second half of 2019.
- 5The company is also presenting at investor conferences, potentially sharing information included in Exhibit 99.1.
Frequently Asked Questions
The LUNAR assay is a new blood-based test developed by Guardant Health aimed at detecting early-stage cancer and monitoring disease recurrence. Its availability for research use allows biopharmaceutical companies and academic institutions to explore its applications in areas like adjuvant therapy decision-making, recurrence monitoring, and screening, potentially accelerating its path to clinical adoption.
Guardant Health expects to launch the clinical version of the LUNAR assay for use in prospective studies in the second half of 2019.
The LUNAR assay's development is informed by biological insights derived from over 80,000 cancer patients who have undergone Guardant360 testing, along with learnings from whole-genome sequencing liquid biopsy data.
Item 7.01 indicates that Guardant Health representatives will be presenting at investor conferences and other forums, and these presentations may include information contained in Exhibit 99.1, which is a set of presentation slides dated January 2019. This is a standard disclosure to inform investors about ongoing business development and communication.